SCHEMBL30871010

SCHEMBL30871010

Nc1cc(N)c2nccn2c1

nearest known ligand 0.50

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
NUDT1 P36639 1/20 0.50
L3MBTL1 Q9Y468 1/20 0.44
AURKA O14965 2/20 0.36
PIK3R1 P27986 1/20 0.36
PIK3CA P42336 1/20 0.36
DYRK1A Q13627 1/20 0.36
CD63 P08962 4/20 0.35
SYK P43405 4/20 0.35
SMPD3 Q9NY59 1/20 0.34
ALDH1A1 P00352 1/20 0.33
POLB P06746 1/20 0.33
GFER P55789 1/20 0.33
HTR2C P28335 1/20 0.33
TNKS O95271 1/20 0.33
KEAP1 Q14145 1/20 0.32
RAB9A P51151 1/20 0.32
KMT2A Q03164 1/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL24077214 0.82 L3MBTL1 (0.62) NUDT1L3MBTL1AURKAPIK3R1PIK3CA
SCHEMBL25310547 0.82 NUDT1 (0.45) NUDT1L3MBTL1AURKAPIK3R1PIK3CA
SCHEMBL26650673 0.82 L3MBTL1 (0.49) NUDT1L3MBTL1AURKAPIK3R1PIK3CA
SCHEMBL25310988 0.82 NUDT1 (0.45) NUDT1L3MBTL1AURKAPIK3R1PIK3CA
Hydrochloric Acid SCHEMBL31600948 0.80 NUDT1 (0.44) NUDT1L3MBTL1AURKAPIK3R1PIK3CA
Hydrochloric Acid SCHEMBL30431775 0.80 L3MBTL1 (0.61) NUDT1L3MBTL1AURKAPIK3R1PIK3CA
SCHEMBL13771121 0.79 NUDT1 (0.47) NUDT1L3MBTL1AURKAPIK3R1PIK3CA
SCHEMBL2914112 0.79 L3MBTL1 (0.65) NUDT1L3MBTL1AURKAPIK3R1PIK3CA
SCHEMBL13821670 0.79 L3MBTL1 (0.50) NUDT1L3MBTL1AURKAPIK3R1PIK3CA
SCHEMBL14006669 0.79 NUDT1 (0.47) NUDT1L3MBTL1AURKAPIK3R1PIK3CA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-4709384-A2 COMBINATION THERAPY FOR TREATMENT OF CANCER PMV Pharmaceuticals, Inc. (US) 2026-03-18 EP disclosed
EP-4605392-A1 METHODS FOR TREATING CANCER Antares Therapeutics, Inc. (US) 2025-08-27 EP disclosed
WO-2024238404-A2 COMBINATION THERAPY FOR TREATMENT OF CANCER PMV PHARMACEUTICALS, INC. (US) 2024-11-21 WO disclosed
WO-2024086809-A1 METHODS FOR TREATING CANCER SCORPION THERAPEUTICS, INC. (US) 2024-04-25 WO disclosed